• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Immunol . Fine Analysis of Lymphocyte Subpopulations in SARS-CoV-2 Infected Patients: Differential Profiling of Patients With Severe Outcome

tetano

Editor, Senior Moderator
Front Immunol


. 2022 Jul 15;13:889813.
doi: 10.3389/fimmu.2022.889813. eCollection 2022.
Fine Analysis of Lymphocyte Subpopulations in SARS-CoV-2 Infected Patients: Differential Profiling of Patients With Severe Outcome


Giovanna Clavarino[SUP] 1 [/SUP], Corentin Leroy[SUP] 2 3 [/SUP], Olivier Epaulard[SUP] 4 5 [/SUP], Tatiana Raskovalova[SUP] 1 [/SUP], Antoine Vilotitch[SUP] 2 [/SUP], Martine Pernollet[SUP] 1 [/SUP], Chantal Dumestre-Pérard[SUP] 1 6 [/SUP], Federica Defendi[SUP] 1 [/SUP], Marion Le Maréchal[SUP] 4 [/SUP], Audrey Le Gouellec[SUP] 5 7 [/SUP], Pierre Audoin[SUP] 8 [/SUP], Jean-Luc Bosson[SUP] 5 [/SUP], Pascal Poignard[SUP] 6 9 [/SUP], Matthieu Roustit[SUP] 10 11 [/SUP], Marie-Christine Jacob[SUP] 1 [/SUP], Jean-Yves Cesbron[SUP] 1 [/SUP]



Affiliations

Abstract

COVID-19 is caused by the human pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has resulted in widespread morbidity and mortality. CD4[SUP]+[/SUP] T cells, CD8[SUP]+[/SUP] T cells and neutralizing antibodies all contribute to control SARS-CoV-2 infection. However, heterogeneity is a major factor in disease severity and in immune innate and adaptive responses to SARS-CoV-2. We performed a deep analysis by flow cytometry of lymphocyte populations of 125 hospitalized SARS-CoV-2 infected patients on the day of hospital admission. Five clusters of patients were identified using hierarchical classification on the basis of their immunophenotypic profile, with different mortality outcomes. Some characteristics were observed in all the clusters of patients, such as lymphopenia and an elevated level of effector CD8[SUP]+[/SUP]CCR7[SUP]-[/SUP] T cells. However, low levels of T cell activation are associated to a better disease outcome; on the other hand, profound CD8[SUP]+[/SUP] T-cell lymphopenia, a high level of CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T-cell activation and a high level of CD8[SUP]+[/SUP] T-cell senescence are associated with a higher mortality outcome. Furthermore, a cluster of patient was characterized by high B-cell responses with an extremely high level of plasmablasts. Our study points out the prognostic value of lymphocyte parameters such as T-cell activation and senescence and strengthen the interest in treating the patients early in course of the disease with targeted immunomodulatory therapies based on the type of adaptive response of each patient.

Keywords: COVID-19; SARS-CoV-2; disease severity; flow cytometry; lymphocytes.
 
Back
Top Bottom